Drugs That Act on the Immune System. Cytokines and Monoclonal Antibodies

Side Effects of Drugs Annual

Volumn 37, Issue , 2015, Pages 461-470

  Jha, Lokesh K ^a   Mukherjee, Sandeep ^b  

^a SANFORD RESEARCH   (United States)

^b CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Abciximab; Adalimumab; Adverse reactions; Alemtuzumab; Bevacizumab; Bone morphogenic proteins; Certolizumab; Cetuximab; Colony stimulating factors; Cytokines; Daclizumab; Etanercept; Golimumab; Infliximab; Interferons; Interleukins; Monoclonal antibodies; Natalizumab; Ranibizumab; Rituximab; Tocilizumab; Trastuzumab; Tumor necrosis factor alfa

Indexed keywords

EID: 84978975420     PISSN: 03786080     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.seda.2015.08.006     Document Type: Chapter

References (111)

1. Rostaing L., Sanchez-Fructuoso A., Franco A., et al. Conversion to tacrolimus once-daily from cyclosporin in stable kidney transplant recipients: a multicenter study. Transpl Int 2012, 25(4):391-400. [C].
2. Nandyala S.V., Marquez-Lara A., Fineberg S.J., et al. Prospective, randomized, controlled trial of silicate-substituted calcium phosphate versus rhBMP-2 in a minimally invasive transforaminal lumbar interbody fusion. Spine 2014, 39(3):185-191. [C].
3. Akilov O.E., Desai N., Jaffe R., et al. Bullous Sweet's syndrome after granulocyte colony-stimulating factor therapy in a child with congenital neutropenia. Pediatr Dermatol 2014, 31(2):e61-2. [A].
4. Kilic S.C., Alaygut D., Unal E., et al. Acute colchicine intoxication complicated with extramedullary hematopoiesis due to filgrastim in a child. J Pediatr Hematol Oncol 2014, 36(7):e460-2. [A].
5. Bondarenko I., Gladkov O.A., Elsaesser R., et al. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy. BMC Cancer 2013, 13:386. [C].
6. Duval C., Boucher S., Moulin J.C., et al. Fatal stimulation of acute myeloid leukemia blasts by pegfilgrastim. Anticancer Res 2014, 34(11):6747-6748. [A].
7. Kozielewicz D., Zalesna A., Dybowska D. Can pegylated interferon alpha 2a cause development of thyroid disorders in patients with chronic hepatitis B?. Expert Opin Drug Saf 2014, 13(8):1009-1014. [c].
8. de Escalona Munoz, Rojas J.E., Garcia Serrano J.L., et al. Application of interferon alpha 2b in conjunctival intraepithelial neoplasia: predictors and prognostic factors. J Ocul Pharmacol Ther 2014, 30(6):489-494. [c].
9. Koktekir B.E., Sumer S., Bakbak B., et al. Ocular effects of pegylated interferon-alpha in patients with chronic hepatitis B. Cutan Ocul Toxicol 2013, 32(4):275-278. [c].
10. Degen A., Weichenthal M., Ugurel S., et al. Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial). J Dtsch Dermatol Ges 2013, 11(9):846-853. [c].
11. Mazzon E., Guarneri C., Giacoppo S., et al. Severe septal panniculitis in a multiple sclerosis patient treated with interferon-beta. Int J Immunopathol Pharmacol 2014, 27(4):669-674. [A].
12. Kambayashi Y., Fujimura T., Ishibashi M., et al. Eosinophilic cellulitis induced by subcutaneous administration of interferon-beta. Acta Derm Venereol 2013, 93(6):755-756. [A].
13. Hunt D., Kavanagh D., Drummond I., et al. Thrombotic microangiopathy associated with interferon beta. N Engl J Med 2014, 370(13):1270-1271. [S].
14. Nerrant E., Charif M., Ramay A.S., et al. Hemolytic uremic syndrome: an unusual complication of interferon-beta treatment in a MS patient. J Neurol 2013, 260(7):1915-1916. [A].
15. Cortellini G., Amadori A., Comandini T., et al. Interferon beta 1a anaphylaxis, a case report. Standardization of non-irritating concentration for allergy skin tests. Eur Ann Allergy Clin Immunol 2013, 45(5):181-182. [A].
16. Rubin S., Lacraz A., Galantine V., et al. Malignant hypertension and interferon-beta: a case report. J Hum Hypertens 2014, 28(5):340-341. [A].
17. Michailidou D., Voulgarelis M., Pikazis D. Exacerbation of interstitial granulomatous dermatitis with arthritis by anakinra in a patient with diffuse large B-cell lymphoma. Clin Exp Rheumatol 2014, 32(2):259-261. [A].
18. Aly L., Iking-Konert C., Quaas A., et al. Subacute liver failure following anakinra treatment for adult-onset Still disease. J Rheumatol 2013, 40(10):1775-1777. [A].
19. Neel A., Henry B., Barbarot S., et al. Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: a French multicenter study. Autoimmun Rev 2014, 13(10):1035-1041. [c].
20. Bene J., Moulis G., Auffret M., et al. Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database. Rheumatology (Oxford) 2014, 53(8):1465-1469. [c].
21. Nardone B., Hammel J.A., Raisch D.W., et al. Melanoma associated with tumour necrosis factor-alpha inhibitors: a Research on Adverse Drug events And Reports (RADAR) project. Br J Dermatol 2014, 170(5):1170-1172. [c].
22. Ellard R., Ahmed A., Shah R., et al. Suicide and depression in a patient with psoriasis receiving adalimumab: the role of the dermatologist. Clin Exp Dermatol 2014, 39(5):624-627. [A].
23. Dias O.M., Pereira D.A., Baldi B.G., et al. Adalimumab-induced acute interstitial lung disease in a patient with rheumatoid arthritis. J Bras Pneumol 2014, 40(1):77-81. [A] por.
24. Abdallah T., Abdallah M., Saifan C., et al. Hemidiaphragm paresis and granulomatous pneumonitis associated with adalimumab: a case report. Heart Lung 2014, 43(1):84-86. [A].
25. Ray M., Curtis J.R., Baddley J.W. A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab. Ann Rheum Dis 2014, 73(7):1429-1430. [A].
26. Nardone R., Zuccoli G., Brigo F., et al. Cerebral toxoplasmosis following adalimumab treatment in rheumatoid arthritis. Rheumatology (Oxford) 2014, 53(2):284. [A].
27. Kobak S., Karaarslan A., Aktakka Y. Renal cell carcinoma in a patient with rheumatoid arthritis treated with adalimumab. Curr Drug Saf 2014, 9(1):69-72. [A].
28. Dicaro D., Bowen C., Dalton S.R. Dermatomyositis associated with anti-tumor necrosis factor therapy in a patient with psoriasis. J Am Acad Dermatol 2014, 70(3):e64-5. [A].
29. Santos G., Sousa L.E., Joao A.M. Exacerbation of recalcitrant cutaneous sarcoidosis with adalimumab-a paradoxical effect? A case report. An Bras Dermatol 2013, 88(6 Suppl 1):26-28. [A].
30. Maruthappu T., Leandro M., Morris S.D. Deterioration of vitiligo and new onset of halo naevi observed in two patients receiving adalimumab. Dermatol Ther 2013, 26(4):370-372. PubMed PMID: 23914896. Epub 2013/08/07.eng [A].
31. Schiff M., Weinblatt M.E., Valente R., et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 2014, 73(1):86-94. [C].
32. Latus J., Klein R., Koetter I., et al. Cholestatic liver disease after rituximab and adalimumab and the possible role of cross-reacting antibodies to Fab 2 fragments. PLoS One 2013, 8(11):e78856. [c].
33. Moisseiev E.S.S. Certolizumab-induced uveitis: a case report and review of the literature. Case Rep Ophthalmol 2014, 5(1):54-59. [A].
34. Lager J., Hilberg O., Lokke A., et al. Severe interstitial lung disease following treatment with certolizumab pegol: a case report. Eur Respir Rev 2013, 22(129):414-416. [A].
35. Glaspole I.N., Hoy R.F., Ryan P.F. A case of certolizumab-induced interstitial lung disease in a patient with rheumatoid arthritis. Rheumatology (Oxford) 2013, 52(12):2302-2304. [A].
36. Kimball A.B., Rothman K.J., Kricorian G., et al. OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. J Am Acad Dermatol 2015, 72(1):115-122. [c].
37. Jin H., Cho H.H., Kim W.J., et al. Primary thyroid marginal zone B-cell lymphoma in a patient with psoriatic arthritis treated with etanercept. J Am Acad Dermatol 2014, 71(4):e152-3. [r].
38. Yahya T.M., Dhanyamraju S., Harrington T.M., et al. Spontaneous resolution of lupus nephritis following withdrawal of etanercept. Ann Clin Lab Sci 2013, 43(4):447-449. [A].
39. Tchernev G., Guarneri C., Bevelacqua V., et al. Carcinoma cuniculatum in course of etanercept: blocking autoimmunity but propagation of carcinogenesis?. Int J Immunopathol Pharmacol 2014, 27(2):261-266. [A].
40. Lora V., Kanitakis J., Latini A., et al. Lichen striatus associated with etanercept treatment of rheumatoid arthritis. J Am Acad Dermatol 2014, 70(4):e90-2. [r].
41. Unterstell N., Bressan A.L., Serpa L.A., et al. Systemic sarcoidosis induced by etanercept: first Brazilian case report. An Bras Dermatol 2013, 88(6 Suppl 1):197-199. [A].
42. Vine K., Dacko A., Weinberg J.M. Nodular fasciitis: a possible side effect of etanercept?. Cutis 2013, 92(4):199-202. [A].
43. Watrin A., Royer M., Legrand E., et al. Severe hypercalcemia revealing sarcoidosis precipitated by etanercept. Rev Mal Respir 2014, 31(3):255-258. Hypercalcemie majeure revelatrice d'une sarcoidose induite par etanercept. fre [A].
44. Durel C.A., Feurer E., Pialat J.B., et al. Etanercept may induce neurosarcoidosis in a patient treated for rheumatoid arthritis. BMC Neurol 2013, 13:212. [A].
45. Couderc M., Mathieu S., Dubost J.J., et al. Retroperitoneal fibrosis during etanercept therapy for rheumatoid arthritis. J Rheumatol 2013, 40(11):1931-1933. [A].
46. Dragnev D., Barr D., Kulshrestha M., et al. Sarcoid panuveitis associated with etanercept treatment, resolving with adalimumab. BMJ Case Rep 2013, 2013. [A].
47. Anazawa R., Suzuki M., Miwa H., et al. A case of esophageal and intestinal tuberculosis that occurred during treatment of rheumatoid arthritis with etanercept. Kekkaku 2014, 89(8):711-716. [A].
48. Sky K., Arroyo R.A., Collamer A.N. Salmonella septic arthritis in a patient receiving etanercept: case report and review of the literature. Mil Med 2013, 178(12):e1384-7. [A].
49. Crusio R.H., Singson S.V., Haroun F., et al. Herpes simplex virus encephalitis during treatment with etanercept. Scand J Infect Dis 2014, 46(2):152-154. [A].
50. Pamies A., Castro S., Poveda M.J., et al. Leucocytoclastic vasculitis associated with golimumab. Rheumatology (Oxford) 2013, 52(10):1921-1923. [c].
51. Uyanikoglu A., Ermis F., Akyuz F., et al. Infliximab in inflammatory bowel disease: attention to adverse events. Eur Rev Med Pharmacol Sci 2014, 18(16):2337-2342. [c].
52. Lim C.S., Moon W., Park S.J., et al. A rare case of free bowel perforation associated with infliximab treatment for structuring Crohn's disease. Korean J Gastroenterol 2013, 62(3):169-173. [A].
53. Yilmaz B., Roach E.C., Koklu S. Infliximab leading to autoimmune hepatitis: an increasingly recognized side effect. Dig Dis Sci 2014, 59(10):2602-2603. [r].
54. Rowe B.W., Gala-Lopez B., Tomlinson C., et al. Fulminant hepatic failure necessitating transplantation following the initiation of infliximab therapy: a cautionary tale times two. Transpl Int 2013, 26(12):e110-2. [r].
55. Colina F., Molero A., Casis B., et al. Infliximab-related hepatitis: a case study and literature review. Dig Dis Sci 2013, 58(11):3362-3367. [A].
56. Dang L.J., Lubel J.S., Gunatheesan S., et al. Drug-induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis. Australas J Dermatol 2014, 55(1):75-79. [A].
57. Sonoda K.H., Fukuhara T., Yoshikawa H., et al. A case report of malignant lymphoma receiving infliximab therapy with Behcet's disease. Nippon Ganka Gakkai Zasshi 2014, 118(5):440-445. [A].
58. Mohammad F., Vivekanandarajah A., Haddad H., et al. Acute promyelocytic leukaemia (APL) in a patient with Crohn's disease and exposure to infliximab: a rare clinical presentation and review of the literature. BMJ Case Rep 2014, 2014. [A].
59. Shah R., Shah M., Bansal N., et al. Infliximab-induced aseptic meningitis. Am J Emerg Med 2014, 32(12):1560.e3-1560.e4. [A].
60. Naruse H., Nagashima Y., Maekawa R., et al. Successful treatment of infliximab-associated immune-mediated sensory polyradiculopathy with intravenous immunoglobulin. J Clin Neurosci 2013, 20(11):1618-1619. [A].
61. Sharma A., Dubey D., Janga K., et al. A case of peritoneal TB causing renal failure in a patient with rheumatoid arthritis and initial negative PPD after treatment with infliximab. Ren Fail 2014, 36(6):948-950. [A].
62. Juzlova K., Votrubova J., Kacerovska D., et al. Visceral leishmaniasis with cutaneous symptoms in a patient treated with infliximab followed by fatal consequences. Dermatol Ther 2014, 27(3):131-134. [A].
63. Yeung D.F., Parsa A., Wong J.C., et al. A case of Rothia dentocariosa bacteremia in a patient receiving infliximab for ulcerative colitis. Am J Gastroenterol 2014, 109(2):297-298. [r].
64. Wang X., Zhao J., Zhu S., et al. Herpes zoster in Crohn's disease during treatment with infliximab. Eur J Gastroenterol Hepatol 2014, 26(2):237-239. [A].
65. Offiah M., Brodell R.T., Campbell L.R., et al. Collodion-like membrane in a newborn exposed to infliximab. J Am Acad Dermatol 2014, 71(1):e22-3. [A].
66. Kakavas S., Balis E., Lazarou V., et al. Respiratory failure due to infliximab induced interstitial lung disease. Heart Lung 2013, 42(6):480-482. [A].
67. Carvalho C.L., Ortigosa L.C. Segmental vitiligo after infliximab use for rheumatoid arthritis-a case report. An Bras Dermatol 2014, 89(1):154-156. [A].
68. Ladizinski B., Lee K.C. Infliximab-induced urticaria. J Emerg Med 2014, 46(5):691-692. [A].
69. Ormaechea-Perez N., Lopez-Pestana A., Munagorri-Santos A.I., et al. Alopecia areata in a patient receiving infliximab. Indian J Dermatol Venereol Leprol 2013, 79(4):529-531. [r].
70. Choi A.W., Blair J.E., Flaherty J.D. Abciximab-induced alveolar hemorrhage treated with rescue extracorporeal membranous oxygenation. Catheter Cardiovasc Interv 2015, 85(5):828-831. [A].
71. Park S., Lee J., Lee S.Y., et al. Acute profound thrombocytopenia after using abciximab for no-reflow during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Korean Circ J 2013, 43(8):557-560. [A].
72. Daley B., Miranda D., Kalra A., et al. Profound thrombocytopenia caused by abciximab infusion following. Minn Med 2014, 97(10):48-49. [A].
73. Willis M., Robertson N.P. Drug safety evaluation of alemtuzumab for multiple sclerosis. Expert Opin Drug Saf 2014, 13(8):1115-1124. [R].
74. Ronchetti A.M.H.B., Ambert-Balay K., Pothier P., et al. Norovirus-related chronic diarrhea in a patient treated with alemtuzumab for chronic lymphocytic leukemia. BMC Infect Dis 2014, 14:239. [A].
75. Fiegl M., Stauder R., Steurer M., et al. Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients. Ann Hematol 2014, 93(2):267-277. [c].
76. Roux C., Thyss A., Gari-Toussaint M. Prostatic and renal aspergillosis due to Aspergillus fumigatus in a patient receiving alemtuzumab for chronic lymphocytic leukaemia. J Mycol Med 2013, 23(4):270-273. [A].
77. Vaccaro V., Fabi A., Vidiri A., et al. Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas. BioMed Res Int 2014, 2014:351252. [c].
78. Gligorov J., Doval D., Bines J., et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncol 2014, 15(12):1351-1360. [C].
79. Wang T.S., Lei W., Cui W., et al. A meta-analysis of bevacizumab combined with chemotherapy in the treatment of ovarian cancer. Indian J Cancer 2014, 51(Suppl 3):e95-8. [M].
80. Qi W.X., Shen Z., Tang L.N., et al. Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups. Eur J Clin Pharmacol 2014, 70(8):893-906. [M].
81. Koyama N. Adverse cardiovascular events predict survival benefit in non-small lung cancer patients treated with bevacizumab. Cancer Biomark 2014, 14(4):259-265. [c].
82. Tomita M., Ochiai M., Shu S., et al. A case of thrombotic microangiopathy with glomerular subendothelial IgA deposition due to bevacizumab. Nihon Jinzo Gakkai Shi 2014, 56(5):612-617. [A].
83. Kiuru M., Schwartz M., Magro C. Cutaneous thrombogenic vasculopathy associated with bevacizumab therapy. Dermatol Online J 2014, 20(6). [A].
84. Miyamoto S. Bevacizumab-induced reversible posterior leukoencephalopathy syndrome in a patient with metastatic colorectal cancer. Nihon Shokakibyo Gakkai Zasshi 2014, 111(4):743-747. [A].
85. Makino T., Kudo S., Ogata T. Pneumothorax after treatment with bevacizumab-containing chemotherapy for breast cancer-a case report. Gan To Kagaku Ryoho 2014, 4(2):233-235. [A].
86. Tamura S., Kusaba H., Kubo N., et al. Interstitial pneumonia during bevacizumab-based chemotherapy for colorectal cancer. Med Oncol 2014, 31(3):856. [c].
87. Fluxa C.D., Salas M.S., Regonesi M.C., et al. Portal vein thrombosis and nodular regenerative hyperplasia associated with the use of bevacizumab and oxaliplatin. Report of one case. Rev Med Chil 2013, 141(10):1344-1348. [A].
88. Matthews J.L., Dubovy S.R., Goldberg R.A., et al. Histopathology of streptococcus mitis/oralis endophthalmitis after intravitreal injection with bevacizumab: a report of 7 patients. Ophthalmology 2014, 121(3):702-708. [c].
89. Cleaver N., Ramirez J., Gildenberg S. Cutaneous lupus erythematosus in a patient undergoing intravitreal bevacizumab injections: case report and review of the literature. J Drugs Dermatol 2013, 12(9):1052-1055. [A].
90. Yamato F., Imai D., Mori K., et al. Corneal subepithelial infiltrates that developed following intravitreous injection of bevacizumab. Nippon Ganka Gakkai Zasshi 2013, 117(7):558-560. [A].
91. Lv Z.C., Ning J.Y., Chen H.B. Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials. Tumour Biol 2014, 35(12):11741-11750. [M].
92. Cvetanovic A., Vrbic S., Filipovic S., et al. Clinical benefit of cetuximab and prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer: a single institution analysis. J BUON 2014, 19(1):83-90. [c].
93. Wehler T.C., Graf C., Mohler M., et al. Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective. J Cancer Res Clin Oncol 2013, 139(10):1667-1672. PubMed PMID: 23918349 [c].
94. Babacan T., Turkbeyler I.H., Dag M.S., et al. Cetuximab-induced esophageal ulcer: the first report in literature. Libyan J Med 2014, 9:23723. [A].
95. Shablak A., Conn A. A case of fatal cetuximab-induced interstitial lung disease during the first weeks of treatment. Target Oncol 2014, 9(2):177-180. [A].
96. Oh J., Saidha S., Cortese I., et al. Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis. Neurology 2014, 82(11):984-988. [c].
97. Haghikia A., Langer-Gould A., Rellensmann G., et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol 2014, 71(7):891-895. [c].
98. Cachia D., Izzy S., Berriosmorales I., et al. Drug-induced thrombocytopenia secondary to natalizumab treatment. BMJ Case Rep 2014, 2014. [A].
99. Bujold J., Boivin C., Amin M., et al. Eosinophilic fasciitis occurring under treatment with natalizumab for multiple sclerosis. J Cutan Med Surg 2014, 18(1):69-71. [A].
100. Na A., Hall N., Kavar B., et al. Central nervous system lymphoma associated with natalizumab. J Clin Neurosci 2014, 21(6):1068-1070. [A].
101. Havla J., Hohlfeld R., Kumpfel T. Unusual natalizumab-associated progressive multifocal leukoencephalopathy starting in the brainstem. J Neurol 2014, 261(1):232-234. [r].
102. Thaker A.A., Schmitt S.E., Pollard J.R., et al. Natalizumab-induced progressive multifocal leukoencephalopathy. Clin Nucl Med 2014, 39(7):e365-6. [A].
103. Aslan Bayhan S., Bayhan H.A., Adam M., et al. Marginal keratitis after intravitreal injection of ranibizumab. Cornea 2014, 33(11):1238-1239. [A].
104. Saffra N., Moriarty E. Burkholderia cepacia endophthalmitis, in a penicillin allergic patient, following a ranibizumab injection. BMJ Case Rep 2014, 2014. [A].
105. Seto W.K., Chan T.S., Hwang Y.Y., et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol 2014, 32(33):3736-3743. [c].
106. Guidelli G.M., Fioravanti A., Rubegni P., et al. Induced psoriasis after rituximab therapy for rheumatoid arthritis: a case report and review of the literature. Rheumatol Int 2013, 33(11):2927-2930. [A].
107. Passalia C., Minetto P., Arboscello E., et al. Cardiovascular adverse events complicating the administration of rituximab: report of two cases. Tumori 2013, 99(6). 288e-92e [A].
108. Renard D., Cornillet L., Castelnovo G. Myocardial infarction after rituximab infusion. Neuromuscul Disord 2013, 23(7):599-601. [A].
109. Sellier-Leclerc A.L., Belli E., Guerin V., et al. Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome. Pediatr Nephrol 2013, 28(9):1875-1879. [A].
110. Papo M., Bielefeld P., Vallet H., et al. Tocilizumab in severe and refractory non-infectious uveitis. Clin Exp Rheumatol 2014, 32(4 Suppl 84):S75-9. [c].
111. Bonifazi M., Franchi M., Rossi M., et al. Trastuzumab-related cardiotoxicity in early breast cancer: a cohort study. Oncologist 2013, 18(7):795-801. [c].